98%
921
2 minutes
20
Purpose: We evaluate the impact of test target location in assessing rod-mediated dark adaptation (RMDA) along the transition from normal aging to intermediate age-related macular degeneration (AMD). We consider whether RMDA slows because the test locations are near mechanisms leading to or resulting from high-risk extracellular deposits. Soft drusen cluster under the fovea and extend to the inner ring of the ETDRS grid where rods are sparse. Subretinal drusenoid deposits (SDDs) appear first in the outer superior subfield of the ETDRS grid where rod photoreceptors are maximal and spread toward the fovea without covering it.
Design: Cross-sectional.
Participants: Adults ≥ 60 years with normal older maculas, early AMD, or intermediate AMD as defined by the Age-Related Eye Disease Study (AREDS) 9-step and Beckman grading systems.
Methods: In 1 eye per participant, RMDA was assessed at 5° and at 12° in the superior retina. Subretinal drusenoid deposit presence was identified with multi-modal imaging.
Main Outcome Measures: Rod intercept time (RIT) as a measure of RMDA rate at 5° and 12°.
Results: In 438 eyes of 438 persons, RIT was significantly longer (i.e., RMDA is slower) at 5° than at 12° for each AMD severity group. Differences among groups were bigger at 5° than at 12°. At 5°, SDD presence was associated with longer RIT as compared to SDD absence at early and intermediate AMD but not in normal eyes. At 12°, SDD presence was associated with longer RIT in intermediate AMD only, and not in normal or early AMD eyes. Findings were similar in eyes stratified by AREDS 9-step and Beckman systems.
Conclusions: We probed RMDA in relation to current models of deposit-driven AMD progression organized around photoreceptor topography. In eyes with SDD, slowed RMDA occurs at 5° where these deposits typically do not appear until later in AMD. Even in eyes lacking detectable SDD, RMDA at 5° is slower than at 12°. The effect at 5° may be attributed to mechanisms associated with the accumulation of soft drusen and precursors under the macula lutea throughout adulthood. These data will facilitate the design of efficient clinical trials for interventions that aim to delay AMD progression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978854 | PMC |
http://dx.doi.org/10.1016/j.xops.2023.100274 | DOI Listing |
Invest Ophthalmol Vis Sci
September 2025
Department of Ophthalmology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Purpose: To explore the causal links between antihypertension drugs usage and age-related macular degeneration (AMD).
Methods: Multiple genetic analyses, including summary data-based Mendelian randomization (SMR), traditional MR, and colocalization analysis, were used to explore the causal associations between antihypertension drugs and AMD. Clinical data from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES) was applied to refined risk assessment of specific antihypertensive medications in the context of AMD development.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Clin Ther
September 2025
F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philade
Purpose: Cholelithiasis is associated with decreased risk of age-related macular degeneration (AMD). Ursodeoxycholic acid (UDCA), a bile acid used to dissolve cholesterol gallstones, has been shown to be retina-protective in several mouse models. This study sought to determine if UDCA may protect against AMD.
View Article and Find Full Text PDFRetina
September 2025
Retina Division, Stein Eye Institute, University of California of Los Angeles, Los Angeles, California.
Purpose: To describe the clinical and multimodal imaging features of a novel form of macular neovascularization (MNV), designated Type 4 MNV, defined by mixed Type 1 and Type 2 neovascularization (NV), extensive intraretinal anastomotic NV, and central posterior hyaloid fibrosis (CPHF).
Methods: This multicenter retrospective observational case series included patients with neovascular age-related macular degeneration (AMD) exhibiting both Type 1 and 2 MNV and an overlying anastomotic intraretinal NV network. This was confirmed with OCT and OCT angiography (OCTA).
Purpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.